东方生物发预亏，预计2025年年度归母净亏损5.23亿元

Core Viewpoint - Dongfang Biological (688298.SH) announced a projected net loss of 523 million yuan for the fiscal year 2025, attributed to significant investments in strategic development across various technology platforms, foreign exchange losses, reduced interest income contributions, and increased asset depreciation and impairment losses [1] Group 1 - The company expects a net profit attributable to shareholders of the parent company to be -523 million yuan for the year 2025 [1] - The main business of the company continues to develop steadily despite the anticipated losses [1] - The losses are primarily due to ongoing substantial investments in the cultivation period of various industry technology platforms [1] Group 2 - Foreign exchange losses and a decrease in contributions from interest income have negatively impacted profits [1] - The company has also incurred increased depreciation and amortization expenses related to assets [1] - There are provisions for impairment losses on certain assets contributing to the overall net loss [1]